A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

NCT06754644 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

808

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: QL2107
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Keytruda®

Sponsor

Qilu Pharmaceutical Co., Ltd.